Sangamo Therapeutics Inc (SGMO) Stock Analysis

Sangamo Therapeutics Inc (SGMO) is a publicly traded company in the HEALTHCARE sector. It trades at $0.21. This page summarizes the public market data, fundamentals, and frequently asked questions for SGMO, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $0.21

Market Sentiment

Sangamo Therapeutics Inc currently has a Neutral sentiment score of 0.03.

About Sangamo Therapeutics Inc

Sangamo Therapeutics, Inc. is a clinical-stage biotechnology firm headquartered in Brisbane, California, specializing in the development of transformative genomic medicines. Utilizing its innovative platform technologies in gene therapy, cell therapy, genome editing, and genome regulation, Sangamo is dedicated to addressing unmet medical needs and improving patient outcomes. The company's cutting-edge research focuses on advancing therapies for genetic and acquired diseases, positioning it as...

GNG Research Analysis

GNG Research scores Sangamo Therapeutics Inc (SGMO) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for SGMO.

Frequently Asked Questions

Does SGMO pay dividends?

Sangamo Therapeutics Inc (SGMO) does not currently pay a regular dividend.